Anti Inflammatory News and Research

RSS

Takeda launches EDARBYCLOR in the U.S. for treatment of hypertension

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., announced EDARBYCLOR (azilsartan medoxomil and chlorthalidone) is now available by prescription in U.S. pharmacies for the treatment of hypertension to lower blood pressure in adults.

6 Feb 2012

Aggrenox not affected by co-administration of omeprazole: Study

Boehringer Ingelheim presented results of a drug interaction study that found Aggrenox (aspirin/extended-release dipyridamole), an antiplatelet medication, is not affected by the co-administration of omeprazole, a proton pump inhibitor (PPI), frequently used to treat several gastrointestinal conditions. These data were presented at the International Stroke Conference (ISC) in New Orleans.

3 Feb 2012

Nuvo launches Synera in the U.S.

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced the U. S. launch of Synera.

3 Feb 2012

First large study to establish link between infection and stroke in children

Common infections in children pose a high risk of ischemic stroke, according to research presented at the American Stroke Association's International Stroke Conference 2012.

1 Feb 2012

ESC welcomes 'intriguing' study on heart failure

The European Society of Cardiology (ESC) welcomes an "intriguing" study, published today in the Journal of the American College of Cardiology, featuring a completely novel approach for improving endothelial function in heart failure.

31 Jan 2012

CAT can assess exacerbation severity in patients with COPD

Exacerbation severity in patients with chronic obstructive pulmonary disease (COPD) can be reliably assessed with the COPD Assessment Test- (CAT), according to a new study from the UK.

27 Jan 2012

Aspirin may reduce depressive symptoms in survivors of ACS

Aspirin has been commonly used for prevention of cardiovascular disease. Depression has been found to be an important prognostic factor after heart attacks. But what is their relationship? This is addressed by a study published in the 5th 2011 issue of Psychotherapy and Psychosomatics.

24 Jan 2012

CQA derivatives in mate tea kill human colon cancer cells

Could preventing colon cancer be as simple as developing a taste for yerba mate tea? In a recent University of Illinois study, scientists showed that human colon cancer cells die when they are exposed to the approximate number of bioactive compounds present in one cup of this brew, which has long been consumed in South America for its medicinal properties.

24 Jan 2012

Luteolin interferes with cell signaling in colon cancer cells

Luteolin is a flavonoid commonly found in fruit and vegetables. This compound has been shown in laboratory conditions to have anti-inflammatory, anti-oxidant and anti-cancer properties but results from epidemiological studies have been less certain. New research published in BioMed Central's open access journal BMC Gastroenterology shows that luteolin is able to inhibit the activity of cell signaling pathways (IGF and PI3K) important for the growth of cancer in colon cancer cells.

23 Jan 2012

Chronic inflammation combines with DNA methylation to promote development of colorectal cancer

Chronic inflammation combines with DNA methylation, a process that shuts down cancer-fighting genes, to promote development of colorectal cancer, scientists at The University of Texas MD Anderson Cancer Center report today in the advance online publication of the journal Nature Medicine.

23 Jan 2012

Patients with PsA may benefit from new medications and surgeries

Medications or biologic agents that target T-cells, white blood cells involved in the body's immune system, appear to offer significant benefit to patients suffering from psoriatic arthritis (PsA), a type of arthritis that affects up to 48 percent of patients with the skin disease psoriasis, according to a new review article in the Journal of the American Academy of Orthopaedic Surgeons.

19 Jan 2012

Ethanol, nonalcoholic compounds in red wine may reduce risk of vascular disease

Observational epidemiologic studies relating wine and alcohol to health all suffer from the fact that they, of necessity, compare people who prefer certain beverages, but not the beverages themselves. While there have been many intervention trials in animals, randomized trials in humans are less common. Randomized crossover trials, in which each subject receives all interventions in sequence, can be especially important as they tend to avoid baseline differences among subjects and can detect effects of different interventions with smaller numbers of subjects.

18 Jan 2012

Geisinger, InVivo to conduct injectable biocompatible hydrogel preclinical study for PNI

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), and Geisinger Health System today announced a research collaboration to conduct a preclinical study using InVivo's injectable biocompatible hydrogel for the treatment of chronic pain caused by peripheral nerve compression.

17 Jan 2012

Sangart commences MP4CO Phase 1b study in sickle cell disease

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 1b study designed to evaluate the safety of MP4CO treatment in patients with sickle cell disease.

12 Jan 2012

AAN, Wolters Kluwer Health announce launch of Neurology Today for the iPad

The American Academy of Neurology (AAN) and Wolters Kluwer Health today announced the launch of Neurology Today for the iPad, a digital app of the most widely read newspaper for neurologists.

10 Jan 2012

CMS assigns permanent J-code for Savient's KRYSTEXXA to treat RCG

Savient Pharmaceuticals, Inc. today announced that a product-specific billing code, or permanent J-code, for KRYSTEXXA (pegloticase) became available on January 1, 2012.

7 Jan 2012

Non-eosinophilic disease more prevalent in patients with mild-to-moderate asthma

A large percentage of patients with mild-to-moderate asthma have persistently non-eosinophilic disease which may not respond to currently available anti-inflammatory treatments, according to a new study.

6 Jan 2012

First study to elucidate how statins reduce activation of abnormal blood clotting

People with high cholesterol are at risk of heart attack and stroke because atherosclerotic plaques within their arteries can rupture triggering the formation of a blood clot called an occlusive thrombus that cuts off the blood supply to their heart or brain.

5 Jan 2012

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange announced today the successful results of the Phase 1/2 study of its drug candidate CF102 in the treatment of hepatocellular carcinoma.

4 Jan 2012

Ampio completes enrollment phase of Australian Ampion In Knee trials

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced that it is has completed the expanded patient enrollment phase of its Ampion In Knee (AIK) trials in Australia.

3 Jan 2012